Biden Calls for Lower Drug Prices: Should Psychedelics Investors be Concerned?

At the start of July, US President Joe Biden signed an executive order to drive down prescription drug prices, with a wide-reaching impact across healthcare, but should investors in psychedelic medicine be concerned? The government ...

Data Science Driving Innovation in Psychedelic Medicine

Big data has revolutionised healthcare, enhancing treatment safety, efficacy and operational efficiency. The technology has become crucial to accelerate drug discovery and development, underpinning the clinical trials that demonstrate ...

Looking Back on the PSYCH Investor Summit: Research & Development

The industry-leading global event series returned on 7 July, with the PSYCH Investor Summit: Research & Development delivering investor-focused panel discussions, professional networking opportunities, research updates and company ...

The Trajectory and Importance of Psychedelic Clinical Trials

At the end of June, COMPASS Pathways announced it had administered its patented psilocybin-derivative, COMP360, to 216 patients in the largest psilocybin assisted-therapy trial to date. The Phase IIb clinical trial is examining the ...

Tryp Therapeutics to Treat Psychiatric Disorders With Synthetic Psilocybin

This year’s PSYCH Investor Summit: Research & Development presents investors with the opportunity to examine Tryp Therapeutics, a publicly traded pharmaceutical company that develops clinical-stage compounds for illnesses with ...

Braxia Scientific Identifies Short-Term ROI in Psychedelic Medicine

As the excitement builds around the FDA’s potential support of psilocybin-based drugs, ketamine-derived medicines have largely flown under the radar, despite securing regulatory approval back in 2019. Braxia Scientific is one of the ...

PSYCH Investor Summit: Research & Development to Highlight the Latest in Medical Psychedelic Science and Investment Opportunities

Following the success of the inaugural PSYCH Investor Summit: Europe and Asia on 21 April, the industry-leading global event series returns to showcase breakthroughs in psychedelic research and development.   Taking place on 7 July, ...

Awakn Life Sciences Lists on the NEO Exchange

Today, Canadian-based biotechnology company Awakn Life Sciences began trading on the NEO Exchange under the symbol AWKN. The company’s focus is the treatment of addiction with psychedelic drugs, therapies and technologies, in the ...

Rising Tides: North American Drug Regulations and the Impact on Big Psychedelic Business – Part 2

With a watchful eye on shifting regulatory landscapes throughout North America, how might investors or operators interpret proposed or enacted loosening of drug restrictions and the impact on psychedelic business? This two-part series ...

Rising Tides: North American Drug Regulations And The Impact On Big Psychedelic Business – Part 1

With a watchful eye on shifting regulatory landscapes throughout North America, how might investors or operators interpret proposed or enacted loosening of drug restrictions and the impact on psychedelic business? This two-part series ...